An Open-Label Extension Study of Voxelotor Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 14 Nov 2024 Status changed from active, no longer recruiting to discontinued.
- 04 Oct 2024 Status changed from discontinued to active, no longer recruiting.
- 25 Sep 2024 According to a Pfizer media release, status changed from recruiting to discontinued.